Terrence J Bradley MD

PubMed

• Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
  Reid Shaw, James J Yoon, Hannah Johnston, Marta B Davidson, Alexa J Siddon
  Blood Advances. 2025-02-19
• 5 citations
  Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
  Anand A Patel, James J Yoon, Hannah Johnston, Marta B Davidson, Rory M Shallis
  Blood Advances. 2024-07-09
• 1 citations
  Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity.
  Hidehiro Itonaga, Adnan K Mookhtiar, Sarah M Greenblatt, Fan Liu, Concepcion Martinez
  Nature Communications. 2024-04-22

Abstracts/Posters

• A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
  Terrence J Bradley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
  Terrence J Bradley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...
  Terrence J Bradley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
  Terrence J Bradley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018